Product Description
Ranitidine 150mg Capsules: What the Published Guidance Says
Acid-suppression and antiemetic agents supplied as injectables and orals, including the proton-pump inhibitor and the two antiemetics carried on the WHO Model List.
Buyers usually settle three things before ordering Ranitidine 150mg Capsules: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.
- Omeprazole is the listed proton-pump inhibitor Section 17.1 of the Model List carries omeprazole as powder for injection 40 mg in vial, powder for oral liquid, and solid oral dosage forms of 10, 20 and 40 mg, for gastro-oesophageal reflux disease. It was first added in 2009. Therapeutic alternatives are the A02BC proton-pump inhibitor subgroup, excluding combinations. The 2025 revision replaced the 20 mg and 40 mg oral-liquid sachets with 1 mg/mL and 4 mg/mL powders for oral liquid. WHO eEML — Omeprazole
- A note on ranitidine Ranitidine appears in section 17.1 of the Model List as an antiulcer medicine, with injection, oral liquid and 150 mg tablet presentations. Since 2020 it has been subject to market-level regulatory action in several countries relating to nitrosamine (NDMA) impurities. Confirm current local registration and monograph status before ordering. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- The antiemetics and their age limits Section 17.2 carries metoclopramide injection 5 mg/mL in 2 mL ampoule and 10 mg tablets, with a Model List note that it is not for use in neonates. Ondansetron is listed as injection 2 mg base/mL in 2 mL ampoule, oral liquid 4 mg base/5 mL, and solid oral forms equivalent to 4, 8 and 24 mg base, indicated above one month of age. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
Each point above is reproduced because it has a practical consequence for Ranitidine 150mg Capsules: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Supply & Specification Data for Ranitidine 150mg Capsules
| Product Name | Ranitidine Capsules 150mg (Ranitidine Hydrochloride 150mg Oral Capsules) |
| Specification | Each capsule contains: Ranitidine Hydrochloride equivalent to Ranitidine 150mg |
| Dosage Form | Oral Hard Gelatin Capsule (for oral administration; swallow whole) |
| Active Ingredient | Ranitidine (as Ranitidine Hydrochloride) |
| Pharmacological Class | H2-Receptor Antagonist (H2 Blocker / Anti-Secretory Agent) |
| Route of Administration | Oral administration (swallow whole with water). May be taken with or without food. Typically taken twice daily (morning and evening) or as a single daily dose, as directed by a healthcare professional. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | GI & Antiemetics — GI & Antiemetics |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Omeprazole 20mg Capsules, Cimetidine Injection 2mL:400mg Ampoule, Omeprazole Powder for Injection 40mg, Metoclopramide Injection 10mg/2mL, Ondansetron Injection 4mg/2mL.
Testing, Monographs & Batch Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Ranitidine 150mg Capsules follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The batch record for this product normally includes:
- Testing for assay of the active substance
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Pack Configuration, Artwork & Shipping Documents
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 10, 20, 30, or 60 capsules per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Dossier, Authority Filings & Tender Documentation
The legal manufacturer named on every document for Ranitidine 150mg Capsules is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Site Master File and GMP certificate for the manufacturing workshops.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
Ranitidine 150mg Capsules is presented here against gastrointestinal and antiemetic medicines named in the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Buyer Questions about Ranitidine 150mg Capsules
What pack size is available for Ranitidine 150mg Capsules?
Standard commercial packaging for this line is Blister pack (PVC-Alu) or HDPE bottle, typically 10, 20, 30, or 60 capsules per blister pack or bottle. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Ranitidine 150mg Capsules?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Ranitidine 150mg Capsules support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Do you supply both ondansetron and metoclopramide?
Yes, as injectables and in oral form. Note the Model List age limits: metoclopramide is not for neonates, and ondansetron is listed above one month of age.
Can you supply ranitidine?
We can supply ranitidine where it is currently registered in the destination market. Several regulators have restricted it since 2020 over nitrosamine impurities, so confirm local status first.
Other GI & Antiemetics Products in This Range
- Omeprazole 20mg Capsules — 20mg
- Cimetidine Injection 2mL:400mg Ampoule — 400mg/2mL
- Omeprazole Powder for Injection 40mg — 40mg
- Metoclopramide Injection 10mg/2mL — 10mg/2mL
- Ondansetron Injection 4mg/2mL — 4mg/2mL
Browse the full GI & Antiemetics range; all Capsules; the complete product catalogue.
Request a Quotation for Ranitidine 150mg Capsules
Tell us the monograph, pack size and quantity required for Ranitidine 150mg Capsules 150mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
- WHO eEML — Omeprazole
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
